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INTRODUCTION
The number of cancer patients admitted to intensive care
units (ICUs) around the world has increased with recent
improvements in cancer therapies. Cancer is now recog-
nized as a chronic disease that is associated with possible
acute decompensation caused by cardiovascular, respira-
tory or infectious disorders, which makes treating these
patients challenging.
1
Pulmonary thromboembolism is a common cause of
morbidity and mortality in cancer patients and is mainly
caused by pulmonary hypertension and right ventricle
dysfunction. A submassive embolism in a cancer patient
may increase morbidity, delay anticancer therapy, and
decrease the patient’s quality of life.
2
A submassivepulmonaryembolismisdiagnosedwhenthe
patient presents right ventricle failure and pulmonary
hypertension without hemodynamic instability. Treatment
with thrombolytic agents during routine medical practice has
altered the natural treatment course for massive and
submassive pulmonary embolism. Thrombolysis is currently
the standard treatment for patients with a massive throm-
boembolism, and this treatment is associated with a
significant reduction in mortality. However, thrombolytic
treatment for submassive embolisms remains controver-
sial.
2,3 Konstantinides et al
3 published a study reporting
better outcomes in patients with submassive pulmonary
embolism that were treated with thrombolysis, including a
decreased need for mechanical ventilation and vasopressor
use, as compared to anticoagulation alone.
3 However, in
cancer patients, thrombolysis may be associated with an
increased risk of bleeding.
4 The incidences of coagulopathy,
thrombocytopenia, and hemorrhagic disorders in cancer
patients are significantly higher compared to patients with-
out cancer, what results in a higher risk of fatal bleeding.
5 For
example, patients with brain metastasis of a solid tumor
should never be treated with thrombolysis; thus, many
cancer patients are ineligible for this treatment.
6,7
Here, we describe four oncology patients with acute
submassive pulmonary embolisms who were treated with
alteplase and heparin. The aim of this study was to assess
thrombolytic therapy in patients with a solid metastatic
tumor, thereby assessing its potential therapeutic benefit in
cancer patients with venous thromboembolism.
PATIENTS AND METHODS
The Local Ethics Committee of our hospital approved this
study.
Four patients who developed or were admitted for a
submassive pulmonary embolism to the Instituto do Cancer
do Estado de Sao Paulo Intensive Care Unit (ICU) in Brazil
between January 2009 and October 2010 were enrolled in this
study. A submassive PE was defined as an acute throm-
boembolism with evidence of right ventricular dysfunction
and no evidence of hemodynamic instability (no need for
vasopressors).
7-9
The patients’ clinical parameters were prospectively
collected and included each patient’s demographic data,
preexisting medical conditions, cancer status, previous
cancer treatment, functional scores, risk scores, and organ
dysfunction. At the time of admission, the patient’s family
members were questioned about the patient’s status perfor-
mance using the Karnofsky performance status scale.
10
Echocardiography was used to evaluate right ventricular
dysfunction. Moreover, cardiac biomarkers, including tropo-
nin, creatine-kinase MB (CKMB) and brain-type natriuretic
peptide (BNP) were quantified. A pulmonary thromboem-
bolism was confirmed by contrast-enhanced computed
tomography (CT) of the chest (Figure 1).
A central venous catheter and an indwelling arterial
catheter were placed in all of the patients. Either a
pulmonary arterial catheter or a minimally invasive cardiac
output measurement device (Vigileo-FloTrac) was used to
monitor the cardiac output. Fluid management and the use
of vasopressors or inotropic agents were applied according
to the ICU’s specific protocols.
Alteplase (Actilyse, Boehringer Ingelheim Pharma) was
administered as deemed necessary by the ICU physician
team. A 10 mg bolus followed by a 90 mg intravenous
infusion over a period of two hours was administered,
resulting in a total dose of 100 mg. Unfractionated heparin
was continually administered at a rate of 12 U/kg/h, and
the rate was subsequently adjusted to maintain an active
partial thromboplastin time 2.0- to 2.5-fold above the normal
upper limit.
6,7 After 24 hours, if there were no bleeding
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1283complications or renal failure, heparin treatment was
replaced by treatment with 1 mg/kg of enoxaparin twice a
day subcutaneously. The patient’s general clinical para-
meters and hemodynamic parameters were monitored for
24 hours after thrombolysis. The hemoglobin level, coagu-
logram and platelet count were analyzed every 4 hours. An
echocardiogram and a CT were performed prior to
thrombolysis and 24 hours after treatment.
Demographic and Clinical Data
Four patients were admitted to the ICU for a submassive
pulmonary embolism (Table 1). The age of the patients
Figure 1 - Contrast-enhanced computed tomography of the chest (Patient 4).
Table 1 - Patient characteristics.
Patient # 12 3 4
Age (years) 70 39 21 83
Gender FM F M
Neoplasm Rectal cancer Lung cancer Osteosarcoma Rectal cancer
Metastasis Liver, retroperitoneum Cervical and Thoracic
Lymph nodes
Bone,
Liver
Absent
Comorbidities Hypertension, Diabetes Absent Absent Chronic coronary
disease
Karnofsky score (at least 30 days
before ICU admission)
90 70 50 90
Chemotherapy (at least 4 weeks
before hospitalization)
Yes No No Yes
Active disease Yes Yes Yes Yes
F: female; M: male; ICU: intensive care unit.
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1284ranged from 21 to 83 years, and two of the patients were
male. All of the patients had an active solid tumor, and three
of the patients had metastatic cancer. None of the patients
had major comorbidities, and the patients’ performance
statuses, as evaluated by the Karnofsky scale, ranged from
50 to 90. Two patients received chemotherapy at least 30
days prior to ICU admission.
Chest pain and dyspnea were the most common
symptoms reported for all of the patients (Table 2). At the
time of presentation, two patients had a systolic blood
pressure less than 90 mmHg, which normalized after fluid
therapy. Echocardiography indicated right ventricular
dysfunction and pulmonary hypertension in all of the
patients. The systolic pulmonary arterial pressure, which
was evaluated with echocardiography, ranged from 50 to 73
mmHg. No patient presented left ventricular dysfunction
during the imaging studies, and two patients presented
mildly elevated cardiac biomarker levels. The troponin level
was measured immediately after ICU admission, and the
values ranged between 0.01 and 0.09 ng/mL. The CKMB
level ranged between 1.8 and 4.7 ng/mL. The brain
natriuretic peptide level was analyzed at admission, and
the data ranged between 62 and 187 pg/mL. Concomitant
deep venous thrombosis was found in all of the patients,
and one of the patients had a prior deep vein thrombosis.
This patient also had a previous pulmonary thromboembo-
lism and received vitamin K antagonists.
All of the patients received systemic thrombolytic therapy
with alteplase and anticoagulation with unfractionated
heparin. An echocardiography that was performed 24 hours
after thrombolysis indicated that all of the patients had
visible recovery of right ventricular dysfunction and
decreased pulmonary hypertension (range 23 to 50 mmHg).
Three of the patients presented total vascular reperfusion, as
was evident in the CT (Figure 1). Onepatient witha recurrent
pulmonary thromboembolism received an inferior vena cava
filter. None of the patients required thrombectomy, surgical
embolectomy, mechanical ventilation or dialysis. There were
no occurrences of intracranial bleeding, gastrointestinal or in-
hospital bleeding. The hemoglobin level slightly decreased
after thrombolytic therapy (mean hemoglobin decrease of
0.8 g/dL), although this decrease was not clinically signifi-
cant. One patient (number 3 in Table 1) died 10 days after
thrombolysis due to progressive cancer and multiple organ
failure. This patient had liver and bone metastasis, and after
10 days, she developed multiple organ failure and died.
DISCUSSION
Although the data regarding thrombolysis treatment in
patients with a submassive pulmonary thromboembolism
are not definitive,
11,12 our data here illustrate the potential
benefits of thrombolytic therapy in cancer patients. A large
controlled clinical trial is needed to confirm the role of
thrombolytic therapy in submassive pulmonary embolism.
However, our data show that if a careful screen for potential
bleeding is performed, this therapy may be safe andeffective,
even in critically ill cancer patients.
13-16
Our patients presented significant clinical improvement
after thrombolysis, which was confirmed by a rapid recovery
of right ventricular function. Thrombolysis was relatively
rapidly administered after the onset of the symptoms, which
may explain the clinical success observed in these patients.
The use of submassive thromboembolism treatment has
been controversial for decades.
11,12 In a controlled ran-
domized trial with 256 patients, Konstantinides et al
3
compared heparin plus alteplase to heparin treatment alone
in patients with a submassive pulmonary embolism using a
composite primary end-point that included in-hospital
death and clinical deterioration requiring escalation of
care.
3 This study indicated that patients who received
heparin and alteplase showed more improvement com-
pared to patients who received heparin alone; however,
there was no difference in the mortality rate for the two
groups of patients. The number of patients with cancer in
this study was not reported.
Patients with cancer must have a minimal performance
status to receive chemotherapy and radiotherapy treatment.
A delay in anticancer therapy may result in disease
progression and worse outcomes in these patients. In a study
with 200 patients with a submassive pulmonary embolism,
Kline et al
17 compared heparin alone or alteplase plus
heparin treatment; they observed a higher incidence of
symptomatic persistent pulmonary hypertension in the
heparin only group six months after treatment.
17 However,
in this study, only two patients with cancer were treated with
thrombolysis. Pulmonary hypertension due to a pulmonary
embolism may negatively impact the prognosis of these
patients, and in some patients, pulmonary embolism may be
more common and serious due to the associated cardiotoxi-
city of chemotherapy.
18 Although the Konstantinides et al
3
Table 2 - Patient clinical data and outcome.
Variable Data
Symptom presentation (%)
Chest pain 4 (100%)
Dyspnea 4 (100%)
Syncope 0
Cough 0
Hemoptysis 0
Time since symptoms to thrombolysis (median,
hours)
40
Systolic pulmonary artery pressure (mmHg)
Prior to thrombolysis 50 – 73
Post-thrombolysis 23 – 50
Right ventricular hypokinesis (%) 3 (75%)
Right heart thrombus (%) 1 (25%)
Left ventricular ejection fraction (range, %) 54 – 68
Concomitant deep vein thrombosis (%) 3 (75%)
Prior deep vein thrombosis (%) 1 (25%)
Prior pulmonary embolism (%) 1 (25%)
Chronic lung disease (%) 0
Heart failure (%) 0
Trauma within 2 mo. 0
Creatinine .2.0 mg/dL 0
Therapy (%)
Thrombolysis 4 (100%)
Heparin 4 (100%)
Vitamin K antagonist 0
Inferior venous cave filter 1 (25%)
Catheter thrombectomy 0
Surgical embolectomy 0
No reperfusion therapy 0
Mechanical ventilation 0
Dialysis 0
Vasoactive agents (%) 2 (50%)
Dobutamine 2 (50%)
Norepinephrine 0
Vasopressin 0
Epinephrine 0
Hospital mortality 1 (25%)
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1285study did not show a decrease in mortality, the potential
benefit of a lower morbidity in cancer patients treated with
thrombolysis may improve the patient status performance
and therefore allow for further treatment.
3
Mikkola et al
13 compared 57 cancer patients to 254 patients
without cancer who were treated in five clinical trials
between 1985 and 1994 with alteplase or urokinase for
pulmonaryembolism.Therewasnodifferencein the hospital
mortality, recurrent pulmonary embolism or major bleeding
complications between the two groups. Nevertheless, throm-
bolytic therapy in cancer patients may be underused, even in
patients with a massive pulmonary embolism. In an
observational prospective study, Kucher et al
4 analyzed
2,392 patientswithacutepulmonaryembolism,including108
patients with massive pulmonary embolism. Among the
patients with massive PE, 23 patients also had cancer.
However, thrombolysis was administered to only two of
the cancer patients. The author did not report why a majority
of the cancer patients did not receive thrombolytic treatment.
Although the thrombolytic therapy in cancer patients
seems to be safe, many physicians still consider cancer a
contraindication to thrombolysis. There is no evidence that
thrombolysis reduces mortality in this group of patients.
However, thrombolysis decreases pulmonary hypertension,
improves the quality of life, and increases the probability of
continuing anticancer therapy. Further data from controlled
clinical trials are required to make a conclusive decision
regarding the benefits of thrombolytic therapy in cancer
patients.
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